Visualization of the transgene distribution according to the administration route allows prediction of the transfection efficacy and validation of the results obtained

被引:17
作者
Delepine, P
Montier, T
Guillaume, C
Vaysse, L
Le Pape, A
Ferec, C
机构
[1] UBO, INSERM EMIU 01 15, F-29275 Brest, France
[2] CHU Morvan, Brest, France
[3] EFS Bretagne, Brest, France
[4] Fac Med & Biopharm Consulting, INSERM EMIU 00 10, Tours, France
[5] Univ Bordeaux 2, F-33076 Bordeaux, France
关键词
lipoplexes; biodistribution; transfection efficiency; intravenous; endotracheal spray;
D O I
10.1038/sj.gt.3301742
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gene transfer to the lung can be achieved via a systemic, that targets the endothelium, or local, that targets the epithelium, delivery route. In the present study, we followed the distribution of a plasmid after transfection using some of our phosphonolipids, which have previously shown their efficiency in transfecting mouse lungs. The plasmid was radiolabeled and varying combinations of plasmid/phosphonolipid were administered by intravenous injection, or by endotracheal spray. The distribution of radioactive labeling was observed over a time course using a gamma-camera. These images were then correlated with the results for luciferase expression levels in the lungs. In each case, lungs were well targeted. However, whereas an intravenous injection reaches all of the lung immediately, progressive diffusion occurs when the plasmid/phosphonolipid is administered via an aerosol. Elimination of the radioactivity associated with plasmid occurs via the urinary tract after intravenous injections, and via the feces using the aerosol delivery approach. The radioactivity detected in the lungs correlated strongly with transgene expression. Thus, such an imaging technique is a powerful strategy to predict the formulation that will generate the best transfection efficiency. This study reveals that scintigraphic imaging permits both validation of the administration method and the results obtained for each animal, thereby reducing the statistical variability of in vivo experiments.
引用
收藏
页码:736 / 739
页数:4
相关论文
共 18 条
  • [1] Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis:: a double-blind placebo-controlled trial
    Alton, EWFW
    Stern, M
    Farley, R
    Jaffe, A
    Chadwick, SL
    Phillips, J
    Davies, J
    Smith, SN
    Browning, J
    Davies, MG
    Hodson, ME
    Durham, SR
    Li, D
    Jeffery, PK
    Scallan, M
    Balfour, R
    Eastman, SJ
    Cheng, SH
    Smith, AE
    Meeker, D
    Geddes, DM
    [J]. LANCET, 1999, 353 (9157) : 947 - 954
  • [2] Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration
    Barron, LG
    Gagné, L
    Szoka, FC
    [J]. HUMAN GENE THERAPY, 1999, 10 (10) : 1683 - 1694
  • [3] Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
    Bellon, G
    MichelCalemard, L
    Thouvenot, D
    Jagneaux, V
    Poitevin, F
    Malcus, C
    Accart, N
    Layani, MP
    Aymard, M
    Bernon, H
    Bienvenu, J
    Courtney, M
    Doring, G
    Gilly, B
    Gilly, R
    Lamy, D
    Levrey, H
    Morel, Y
    Paulin, C
    Perraud, F
    Rodillon, L
    Sene, C
    So, S
    TouraineMoulin, F
    Schatz, C
    Pavirani, A
    [J]. HUMAN GENE THERAPY, 1997, 8 (01) : 15 - 25
  • [4] GENE-THERAPY FOR CYSTIC-FIBROSIS USING E1-DELETED ADENOVIRUS - A PHASE-I TRIAL IN THE NASAL CAVITY - THE UNIVERSITY-OF-NORTH-CAROLINA AT CHAPEL-HILL
    BOUCHER, RC
    KNOWLES, MR
    JOHNSON, LG
    OLSEN, JC
    PICKLES, R
    WILSON, JM
    ENGELHARDT, J
    YANG, YP
    GROSSMAN, M
    [J]. HUMAN GENE THERAPY, 1994, 5 (05) : 615 - 639
  • [5] Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG(5000) formulation to the lungs of normal volunteers
    Chadwick, SL
    Kingston, HD
    Stern, M
    Cook, RM
    OConnor, BJ
    Lukasson, M
    Balfour, RP
    Rosenberg, M
    Cheng, SH
    Smith, AE
    Meeker, DP
    Geedes, DM
    Alton, EWFW
    [J]. GENE THERAPY, 1997, 4 (09) : 937 - 942
  • [6] Delépine P, 2000, J PHARM SCI, V89, P629
  • [7] DELEPINE P, UNPUB HUM GENE THER
  • [8] Systemic administration of cationic phosphonolipids/DNA complexes and the relationship between formulation and lung transfection efficiency
    Floch, V
    Delépine, P
    Guillaume, C
    Loisel, S
    Chassé, S
    Le Bolc'h, G
    Gobin, E
    Leroy, JP
    Férec, C
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2000, 1464 (01): : 95 - 103
  • [9] Aerosolization of cationic lipid-DNA complexes: lipoplex characterization and optimization of aerosol delivery conditions
    Guillaume, CR
    Delepine, P
    Droal, C
    Montier, T
    Tymen, G
    Claude, F
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 286 (03) : 464 - 471
  • [10] Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice
    Guillaume-Gable, C
    Floch, V
    Mercier, B
    Audrézet, MP
    Gobin, E
    Le Bolc'h, G
    Yaouanc, JJ
    Clément, JC
    Des Abbayes, H
    Leroy, JP
    Morin, V
    Férec, C
    [J]. HUMAN GENE THERAPY, 1998, 9 (16) : 2309 - 2319